Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Deals

Eisai China Partners with Shanghai Pharmaceuticals Holding – Focus on Oncology, Neuroscience and Sleep Disorders

Fineline Cube Nov 8, 2025

In a high‑profile signing at the 8th China International Import Expo (CIIE), Eisai China (TYO:...

Policy / Regulatory

NHSA Pilot AI Review Accelerates Full‑Process Medical Insurance Assessment in 7 Chinese Provinces

Fineline Cube Nov 8, 2025

The National Healthcare Security Administration (NHSA) has announced a three‑phase, AI‑powered review pilot covering Beijing,...

Policy / Regulatory

US FDA’s CNPV Fast‑Track Program Expands to 15 Drugs, Cutting Review Time to Months

Fineline Cube Nov 8, 2025

The Commissioner’s National Priority Voucher (CNPV) pilot has just added 15 therapies to its two‑batch...

Company Deals

Sichuan Biokin Launches on HKEX, Raises HK$3.3 B in $389/Share Offering – A Milestone for China’s Biotech

Fineline Cube Nov 8, 2025

China’s Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced its successful initial public offering (IPO)...

Medical Device

LifeTech Scientific Secures NMPA Approval for G‑Branch TAAA Stent‑Graft System

Fineline Cube Nov 8, 2025

LifeTech Scientific Corporation (HKG: 1302) announced that China’s National Medical Products Administration (NMPA) has granted...

Company

Viatris Posts Q3 2025 Revenue Dip, Highlights Emerging‑Market Branded Growth and Aculys Pharma Acquisition

Fineline Cube Nov 8, 2025

U.S.‑based Viatris Inc. (NASDAQ: VTRS) released its third‑quarter 2025 earnings, showing a 2 % year‑over‑year (YOY)...

Company Drug

Humanwell Healthcare Secures NMPA Approval to Launch First Fixed‑Dose Combination for Pulmonary Arterial Hypertension

Fineline Cube Nov 8, 2025

Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its investigational compound HWH217 has received...

Company Drug

Eli Lilly & Novo Nordisk Reach U.S. Deal to Cut Obesity‑Drug Prices, Unlock Medicare & Medicaid Access

Fineline Cube Nov 8, 2025

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) announced a historic agreement with the...

Medical Device

Johnson & Johnson Launches ETHICON 4000 3D Laparoscopic Stapler in China

Fineline Cube Nov 8, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced today the commercial rollout of its ETHICON 4000 laparoscopic stapler...

Company

BeOne Medicines Posts $1.4 B Q3 2025 Revenue, Driven by BRUKINSA Momentum

Fineline Cube Nov 7, 2025

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) released its third‑quarter 2025 financial results, reporting...

Company Drug

CStone Pharmaceuticals to Unveil CS2015 Data at 2025 ACAA​I Meeting

Fineline Cube Nov 7, 2025

China‑based CStone Pharmaceuticals (HKG: 2616) announced that the pre‑clinical results for its bispecific biologic CS2015...

Company Deals

AmacaThera Signs Exclusive Global License with Pacira BioSciences for AMT‑143, Up to $230 M Deal

Fineline Cube Nov 7, 2025

AmacaThera, the hydrogel‑technology biotech incubated by Viva BioInnovator (VBI), announced an exclusive worldwide licensing agreement...

Others

Sanofi’s Cablivi Wins China NMPA Approval – First Nanobody Drug for aTTP

Fineline Cube Nov 7, 2025

Sanofi (NASDAQ: SNY) announced that its anti‑vWF Nanobody Cablivi (caplacizumab for injection) received formal marketing...

Others

Judge Rejects Pfizer’s Attempt to Block Novo Nordisk’s $10 bn Bid for Metsera

Fineline Cube Nov 7, 2025

Delaware Court of Chancery Judge Morgan Zurn denied Pfizer’s (NYSE: PFE) request for a temporary...

Company

Amgen Reports 12% YoY Sales Growth in Q3 2025, Raises Full‑Year Revenue Guidance

Fineline Cube Nov 7, 2025

US‑based biotech giant Amgen (NASDAQ: AMGN) posted its third‑quarter 2025 results, showing total sales of...

Company

AstraZeneca Posts 11% Y/Y Revenue Rise to $43.24 bn in First Nine‑Months of 2025

Fineline Cube Nov 7, 2025

AstraZeneca (AZ, NASDAQ: AZN) released its third‑quarter and nine‑month 2025 financial results, showing total revenues...

Policy / Regulatory

NHSA Concludes 2025 National Basic Medical Insurance Drug Catalogue Negotiation and Commercial Insurance Innovative Drug Price Talks

Fineline Cube Nov 6, 2025

The National Healthcare Security Administration (NHSA) wrapped up a week‑long series of negotiations and bidding...

Company Deals

XtalPi’s Ailux Strikes $345 Million Partnership with Eli Lilly to Co‑Develop Bispecific Antibodies

Fineline Cube Nov 6, 2025

Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) disclosed that its wholly‑owned subsidiary Ailux...

Medical Device

Siemens Shanghai Gains NMPA Clearance for Prostate‑Cancer AI Detection Software

Fineline Cube Nov 6, 2025

Siemens Shanghai Medical Equipment Ltd. (SSME) announced that the National Medical Products Administration (NMPA) has...

Company Deals

HBM’s Subsidiary Nona Biosciences Teams Up with Umoja Biopharma to Co‑Develop In‑Vivo CAR‑T Platforms

Fineline Cube Nov 6, 2025

HBM Holdings Limited (HKG: 2142) announced that its wholly‑owned subsidiary Nona Biosciences (Suzhou) Co., Ltd....

Posts pagination

1 … 134 135 136 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.